| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Total other income, net | 1,641 | 1,414 | 1,896 | 2,957 |
| Loss before income taxes | -34,386 | -41,443 | -35,907 | -72,704 |
| Provision for income taxes | 0 | 0 | - | - |
| Net loss | -34,386 | -41,443 | -35,907 | -72,704 |
| Earnings per share, basic, total | -0.37 | -0.46 | -0.42 | -1.07 |
| Earnings per share, diluted, total | -0.37 | -0.46 | -0.42 | -1.07 |
| Weighted average number of shares outstanding, basic, total | 93,332,930 | 89,138,568 | 85,697,108 | 68,091,446 |
| Weighted average number of shares outstanding, diluted | 93,332,930 | 89,138,568 | 85,697,108 | 68,091,446 |
Amylyx Pharmaceuticals, Inc. (AMLX)
Amylyx Pharmaceuticals, Inc. (AMLX)